New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
07:07 EDTCRISCuris announces IND filing to initiate Erivedge Phase 2 study
Curis announced that Roche has filed an Investigational New Drug application with the U.S. Food and Drug Administration to initiate a multicenter, Phase 2 clinical study of Erivedge, or vismodegib, in patients with idiopathic pulmonary fibrosis. Roche and Genentech, a member of the Roche Group, develop and commercialize Erivedge under a collaboration agreement with Curis. According to Roche, following FDA review of the IND, the study is anticipated to start enrollment later this year and is expected to enroll approximately 130 patients.
News For CRIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
07:05 EDTCRISCuris doses first patient in CUDC-907 Phase 1 trial
Curis announced that the first patient has initiated treatment with CUDC-907 in a Phase 1 clinical trial in patients with advanced or relapsed solid tumors, including hormone receptor positive/ HER2-negative breast cancer or midline carcinoma with certain NUT gene rearrangements. CUDC-907 is an oral, dual inhibitor of histone deacetylase, or HDAC, and phosphoinositide 3-kinase, or PI3K, enzymes that is currently under investigation in the first-in-human Phase 1 clinical study in patients with relapsed or refractory lymphomas and multiple myeloma.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use